ABSTRACT
INTRODUCTION
The role of minor histocompatibility antigens (mHags) in the context of hematopoietic stem cell transplantation is being intensely studied (Hambach and Goulmy, 2005) . These antigens, which can potentially result from any polymorphic gene, have been implicated in causing the deadly graft versus host disease (GvHD) and present a hurdle for successful treatment of leukemia and other hematopoietic diseases following hematopoietic stem cell transplantation (HSCT) (Goulmy, et al., 1996) . However, these immunological targets also prevent relapse when expressed on the surface of the patient's malignant cells (Spierings, et al., 2004) . Here they are targeted by donor T cells, causing the so called graft ver-* To whom correspondence should be addressed. sus leukemia (GvL) effect. As we have reviewed previously, bioinformatics has become an important tool in investigating mHags . We present here a computational approach to predicting minor histocompatibility antigens, with special attention given to those antigens which cause GvL. This system, named PeptideCheck, considers gene expression, polymorphism data, and antigen presentation prediction algorithms.
A given antigen can promote GvHD or GvL depending on its expression pattern across cell and tissue types. Because liver and epithelial cells are particularly affected by GvHD, it is logical that antigens which are expressed in these cells contribute to GvHD. On the other hand, antigens expressed exclusively in leukemia cells could have a targeted anti-tumor effect without causing GvHD. In fact, antigens specific to hematopoietic cells are also interesting targets for the GvL effect, as long as they only occur in the patient's original blood system, but not in the blood system of the donor after HSCT. This is the situation when hematopoietically expressed antigens are also mHags -i.e. they result from polymorphic mismatches between donor and recipient.
In principle, mHags can result from any genetic polymorphism which leads to differential amino acid expression. Examples involving single nucleotide polymorphisms (SNP) include nonsynonymous nucleotide replacements leading to an amino acid exchange, frame-shift causing nucleotide insertions or deletions, as well as mutations which either disrupt stop codons, or result in premature stop codons. The NCBI's dbSNP polymorphism database and the HapMap project are important resources for such data (Consortium, 2003; Smigielski, et al., 2000) .
In addition to having to fulfill these genetic requirements, mHag candidates must be presented on the cell surface by the antigen presentation machinery (Rock and Goldberg, 1999) . This process begins with proteasomal cleavage of proteins into peptide fragments. These peptides are then selectively loaded into MHC molecules by the transporter associated with antigen processing (TAP) protein. Finally, the MHC-peptide complexes are carried to the cell surface where they can interact with the T cell receptors found on the surface of T lymphocytes. Because each of these steps is selective and dependant on motifs found in the peptide sequences, it has been possible to develop algorithms for predicting the fate of peptide regions (Brusic, et al., 1998; Buus, et al., 2003; Kesmir, et al., 2002; Nussbaum, et al., 2001; Parker, et al., 1994; Peters, et al., 2003; Rammensee, et al., 1999; Zhang, et al., 2006) . Here, we employ the strategy of utilizing the processing scores to filter out a list of the most promising peptides. Finally the best candidates are those which have high processing scores for all applied algorithms, relevant SNP frequencies, and appropriate tissue-specific gene expression.
With regard to technique of integrating databases and algorithms to explore mHags, the state of the art includes systems such as SNEP (Schuler, et al., 2005) and SiPep (Halling-Brown, et al., 2006) . SNEP extracts polymorphism data and sequences from SWISS-PROT (Boeckmann, et al., 2003) and calculates HLA binding using SYFPEITHI (Schuler, et al., 2007) . SiPep utilizes dbSNP data, tissue expression data and combines proteasomal processing with HLA binding predictions. These systems however, are impractical for high throughput analysis. With PeptideCheck, we go several steps further to integrate user-defined gene expression analysis, and batch processing to analyze large amounts of user or public data conveniently.
METHODS
This study required the integration of diverse biological data resources, cleansing and processing of this data, as well as integration of epitope prediction algorithms. This resulted in a large database of annotated peptide candidates which could then be queried using filters based on user criteria in a flexible manner. The dataflow of this system is summarized in Figure  1 .
Prediction algorithms
The following prediction algorithms were applied to the peptide candidates: Proteasomal processing prediction by NetChop (Kesmir, et al., 2002) , and the PepCleave predictor (Ginodi, et al., 2008) . HLA binding prediction was performed with matrixes and modular matrices .
Data sources
SNP Data was imported from NCBI using the HTTP-based querying service, eUtilities. Only human non-synonymous coding SNPs were considered. The NCBI eFetch service was queried using the database dbSNP (Build 128), the format XML, and the TERM: ( Homo+sapiens [Organism] eUtilities were also used to retrieve protein sequences from NCBI for proteins containing SNPs. The genes from the dbSNP which were marked as coming from the Y chromosome were included and tagged as Y-linked. Further Y-linked genes were fed into PeptideCheck by querying NCBI Entrez using the term: 
Generating peptides
Amino acid exchanges were made in the protein sequence. All possible peptides of length 15 containing both variants of the SNP were generated and stored in an InterSystems Caché database. For immunoPaproc, 15 amino acids were required for the calculations, whereby the ninth amino acid represents the C terminus. For immuneepitope database predictions, entire protein sequences were considered. For those SNPs which result in a frame shift or involved stop codons, peptides from the entire protein sequence were included. Such peptides were tagged as located "Before Mutation" (BM), "After Mutation" (AM) or "Containing Mutation" (CM) respectively. Peptides encoded by polymorphic regions are generated and annotated with relevant information, including prediction scores. The system allows peptides to be queried using a (1) a combination of filters, (2) target peptide sequence (e.g. unidentified, eluted peptides), or (3) a ranking based upon HLA binding scores.
SNP frequencies
The genotypic SNP frequency data provided by the dbSNP was supplemented with frequency data directly from the HapMap project (Consortium, 2003) . The data is automatically downloaded from the online repository found at http://www.hapmap.org/downloads/frequencies/latest/rs_strand/nonredundant/, and then unzipped and stored. We chose to change the representation of genotypic frequency data to make it more practical in the context of allogeneic transplantation. We define PP frequency (presence of peptide) to be the sum of the homozygous and heterozygous frequencies of the individuals expression a peptide variant, and the AP frequency (absence of peptide) to be the frequency of individuals who are homozygous negative for the given peptide.
Expression
The cell and tissue expression data presented here were acquired from three sources. The first source is our own analysis of CML, CD34+, primary intestinal epithelial (PIE), normal human epidermal keratinocytes (NHEK) cells using GeneChip HG-U133A probe array (Affymetrix) with human renal proximal tubule cells (RPTEC) cells as control signal. The array contains a probe set for 22,283 oligonucleotide sequences and was utilized according to the manufacturer's recommendations. RNA extracts from each cell type were processed to cDNA by reverse transcription, followed by in vitro transcription using biotinylated nucleoside triphosphates. After hypridization to the array and scanning, the results were interpreted using the MAS 5.0 software (Affymetrix).
A further source of expression data was the LeGeneD (Leukemia Gene Database http://www.bioinformatics.org/legend/) which are designated LEU in our system. The third source of data comes from GeneNotes (Shmueli, et al., 2003) , and the cell types are listed as Bone Marrow and Liver in PeptideCheck.
High throughput minor histocompatibility antigen prediction

GvL ligand ranking
Extracting GvL-relevant ligand candidates from all the peptides in the database involves a combination of filtering and ranking. Firstly, peptides are filtered by the criteria entered by the user -cell/tissue expression, antigen presentation prediction scores, SNP types and frequencies. The genes encoding list of filtered peptides are then ranked by the number of candidate antigens per gene. The resulting peptides can then be browsed gene for gene.
SNP validation
The validation of the SNPs was performed by sequencing-based typing (Horn, et al., 2006) . The PCR products were subsequently sequenced in both forward and reverse directions by cycle sequencing (Big Dye terminator, Applied Biosystems, Foster city, CA) using an Applied Biosystems 3730 sequencer and the data were analyzed by the SeqMan II program version 5.7 (GATC, Konstanz, Germany).
RESULTS
Quantity and quality of data
In total, 48,905 SNP entries were imported from the dbSNP. These SNPs are found within 15,898 genes -roughly half of the estimated number of genes in humans. Because genes can be associated with multiple protein sequences at NCBI, 23,798 proteins were imported. The total number of unique peptide sequences contained in the system is 1,854,676. These and other statistics can be found in Table 1 .
It should be noted that the ratios of proteins to genes in the system simply reflects the way that protein and gene data are reported to NCBI, and do not necessarily reflect biological events (e.g. mutations or alternative splicing, etc.).
Three sources of gene expression data have been included so far. Our own Affymetrix analysis resulted in 2853 CML expressed, 2714 CD34 expressed, 1953 PIE, 2833 NHEK, and 2960 RPTEC expressed genes. Furthermore, 48 leukemia expressed genes were included. Additionally, 5514 bone marrow and 5575 liver genes were included. Finally, 12 Y chromosome associated genes were included. It should be noted that any user may upload any additional gene expression data. 
Coverage of known mHags
Because the goal of this system is to identify possible mHag candidates, it is interesting to investigate whether known mHag peptides are found within the database. The sequences and reference data of known mHags were downloaded from the Minor Histocompatibility Knowledge Database (dbMinor) hosted at the Leiden University Medical Center website (Spierings, et al., 2006) . We searched for these peptide sequences in PeptideCheck to determine whether our data correlate to the published data (Table 2) . There were 29 minors listed in dbMinor which result from 21 unique polymorphisms. All 14 reported coding non-synonymous SNPs from dbMinor were also reflected within the PeptideCheck database. Of the 7 missing SNPs, 2 were simply not reported to the dbSNP (HA-2 and LB-ADIR-1F), excluding them from our system as a result. Because we considered only coding non-synonymous SNPs, it was expected that polymorphisms such as alternative splicing, gene deletion, etc. would not be encompassed in the model. The 5 remaining missing SNPs can be attributed to this kind of model limitation. The mHag encoded by SP110 results from transpeptidation . The mHag encoded by CENPM results from alternative transcription leading to the incorporation of an additional exon (Brickner, et al., 2006) .The two mHags encoded by UGT2B17 are caused by gene deletion (Murata, et al., 2003) . Furthermore, alternative splicing causing an exon deletion in HMSD produces the mHag, ACC-6 (Kawase, et al., 2007) . The minor A33/HY from the gene TMSB4X was not found because it is encoded by an unconventional open reading frame (Torikai, et al., 2004) . The same applies to LB-ADIR-1F. (van Bergen, et al., 2007) .
In several cases, the dbSNP entries used by PeptideCheck to generate known mHags differed from those of the dbMinor, revealing outdated or erroneous SNPs in dbMinor. For HA-3 the originally reported dbSNP entry rs7162168 claims an amino acid exchange at position 1216 in the sequence found in NP_006729. However the actual position of the exchange is 452, which is given in a different dbSNP entry retrieved by our system: rs2061821. For HB-1H and HB-1Y, the reported rs57824 was outdated, but our system identified the correct replacement: rs161557.
Ranking of ligand candidates
To find mHag candidates, the peptides were filtered and ranked. As filtering criteria, the peptides were required to be encoded by a validated missense SNP and have a PepCleave proteasomal processing score above -3.0 (Table 2 was helpful in determining this threshold). The peptides were then ranked according to their HLA binding scores. The best 10 candidates for A*0101 and A*0201 are given in Table 3 .
As a result of this ranking, several of the known mHags could be reproduced. The total number of peptides considered (those resulting from missense SNPs) was 822,299. The mHag, HA-3 was ranked at place 2 binding to HLA*0101. The HLA*0201 binding known mHags HA-8 and HA-1 were found at places 330 and 1,748 respectively. To put these numbers in relation, it should be noted that even place 1,748 is within the top quarter of the top one per cent of the peptides considered.
The major motivation for creating PeptideCheck was to help identify GvL-relevant ligand candidates. GvL-relevance is determined by a cell expression which is specific to hematopoietic tissues, and not present in tissues at risk to GvHD. A PepCleave score of -4.0 was used. An HLA binding score of -22 was applied, which is associated with a specificity of over 99% for HLA-A*0201. Further requirements include both PP and AP frequencies of at least 10%. These filters resulted in the 13 GvL-relevant ligand candidates listed in Table 4 . This table reflects information on the known mHags as reported in the dbSNP (left side) and in PeptideCheck (right side) to illustrate the extent to which PeptideCheck can reflect real mHags.
a. The sequence give is the immunogenetic peptide. The polymorphic residue is given in bold italics.
b.
SNP entries given with a were identical between dbSNP and PeptideCheck. In the cases where PeptideCheck uses a different, but equally correct rs entry, it is given in parenthesis. "Y-linked" does not refer to dbSNP data, but simply that the allogenicity resulting from gender difference. c. Proteasomal processing score by PepCleave. Higher values are better and scores over -4 can be considered good. d. Matrix-based HLA binding score for the mHag associated allele, followed by modular-matrix based prediction in parenthesis. Higher values are better, and scores greater than -27 are quite good. The polymorphic position in the peptide is given in italic bold. Cleavage refers to PepCleave scores. HLA refers to matrix-based HLA binding scores. Pep. Pos is the position of the peptide within the protein sequence. AA pos. is the position of the polymorphic residue within the original protein sequence. Alt. res. is the alternate residue given by the dbSNP entry. The SNP for CARD8 results in a premature stop codon and the reported peptide is downstream from this mutation.
SNP typing results
To determine whether the SNPs of candidate peptides occur with clinically relevant frequencies, sequencing-based SNP typing was performed on blood samples from healthy blood donors. The genes were chosen based upon the number of associated SNPs which lead to peptides with high prediction scores. Sequencing-based typing was performed for a set of SNPs which were reported in the database as validated either by HapMap or by frequency data from the dbSNP. Additionally a set of SNPs with no validation data were typed. In both cases, only those donors were typed for a given SNP when they were previously shown to carry the HLA allele predicted to bind the SNPderived peptide. A selection of SNP typings are shown in Table   5 . Of the 6 previously validated SNPs, all but one were confirmed. None of the non-validated SNPs could be found after 8 to 30 typings. It is also possible for users to upload new tissue or cell type expression data. They can simply upload a list of genes and define with which cell types they are associated. The resulting expression data is then active when the user searches for peptides. 
Web interfaces
DISCUSSION
By providing this compilation of databases and algorithms online at www.peptidecheck.org, we hope to offer the mHag community a resource which can offer practical assistance in discovering and analyzing GvL-relevant peptides. This is the first system offering combined antigen presentation prediction algorithms for mHag analysis and in a manner convenient for high throughput investigation of sequences from experimentally eluted peptides. The novel representation of SNP frequency as PP (presence of peptide) and AP (absence of peptide) frequencies is specific to the situation of allogeneic transplantation, and is practical for quickly determining the clinic relevance of SNP data. Our SNP typing confirmation demonstrates the futility of searching for non-validated SNPs. This underscores the value of the HapMap frequency data, which is reflected in the PP and AP scores in the system. When searching for peptides, the PeptideCheck users can conveniently provide thresholds for these values.
The comparison of the data in this system to that of the dbMinor, which contains data on known mHags, has helped to clarify the extent to which bioinformatic systems can simulate immunogenetic processes. Clearly, coding non-synonymous mutations leading to a single amino acid exchange are well suited to be reproduced using computer algorithms. The situation becomes more complicated when frame shifts, splice cites, or promoter regions are involved. Despite this, PeptideCheck does incorporate insertion / deletion SNPs. Here we have chosen to generate peptides from the full length of the protein sequence, and to designate them as occurring before or after the beginning of the frame shift, or as containing the SNP cite. Most likely, peptides occurring after the frame shift are most likely to be immunogenetic. Since there is no data on this, we simply choose to label the peptides accordingly, and allow the PeptideCheck user to decide.
The matrix-based HLA binding prediction algorithm produced strikingly high scores for known mHags. Ranking our lists of peptide candidates based upon these scores proved to be very successful, if success is measured by the presence of known mHags near the top of the list. The utility of the modular matrix is demonstrated in Table 2 because there was no adequate standard matrix available for B*52 predictions. This is a case where the expanded coverage of the modular matrix is advantageous. Furthermore, additional population coverage is critical to making applications relevant for individual patients, many of whom have low frequency HLA alleles.
The greatest limitation of this system currently is the fact that HLA binding scores are only made for peptides having nine amino acids. However, this analysis was necessary to determine if there is merit in the computational approach to mHag identification. This being the case, we will expand the system to include peptides of different lengths. Furthermore, a database of gene deletion frequencies would greatly augment this system. An important advantage of this automated approach is that it is adaptable to potential forms of individualized medicine. As the price of SNP microarrays decreases, the ability for large scale SNP typing for an individual patient and donor pair becomes reality. Using this input to generate GvL-relevant ligand candidates which could be then synthesized and utilized for ex vivo T-cell stimulation during adoptive transfer offers great potential.
